Literature DB >> 29126507

Surgical options in the treatment of ulcerative colitis.

Daniel P Ryan1, Daniel P Doody2.   

Abstract

Children and young adults with ulcerative colitis tend to present with more extensive colonic disease than an adult population. The need for surgical intervention in the pediatric population with ulcerative colitis occurs earlier after diagnosis and has a greater incidence than a comparably matched adult population with an estimated need for colectomy at 5 years following diagnosis of 14-20%. Perhaps, even more than the adult population, there is a desire to restore intestinal continuity for the pediatric patient to achieve as healthy and normal quality of life as possible. With surgery playing such a prominent role in the treatment of ulcerative colitis in this age group, an understanding of the surgical treatment options that are available is important. The surgeon's awareness of the complexities of the different operations associated with proctocolectomy and reestablishing intestinal continuity may help to avoid early complications and minimize the risk of less than ideal long-term outcomes.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Crohn disease; Ileoanal pouch; Ileostomy; Pediatric ulcerative colitis; Pouchitis; Restorative proctocolectomy

Mesh:

Year:  2017        PMID: 29126507     DOI: 10.1053/j.sempedsurg.2017.10.001

Source DB:  PubMed          Journal:  Semin Pediatr Surg        ISSN: 1055-8586            Impact factor:   2.754


  2 in total

1.  The combined efficacy of adalimumab with GMA method on the treatment of ulcerative colitis and repair of intestinal mucosal lesion.

Authors:  Ailing Song; Hai Jiang; Liang Guo; Shanshan Wu
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

2.  Probiotics combined with aminosalicylic acid affiliates remission of ulcerative colitis: a meta-analysis of randomized controlled trial.

Authors:  Lijun Peng; Yan Zhong; Aiping Wang; Zhisheng Jiang
Journal:  Biosci Rep       Date:  2019-01-18       Impact factor: 3.840

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.